9,520 Shares in Cardinal Health, Inc. $CAH Bought by Vise Technologies Inc.

Posted by Brian Himes on Aug 22nd, 2026

Vise Technologies Inc. acquired a new stake in shares of Cardinal Health, Inc. (NYSE:CAH – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 9,520 shares of the company’s stock, valued at approximately $2,262,000.

A number of other hedge funds have also recently made changes to their positions in CAH. LWM Advisors Inc. lifted its position in Cardinal Health by 4.4% in the 2nd quarter. LWM Advisors Inc. now owns 1,028 shares of the company’s stock valued at $244,000 after acquiring an additional 43 shares in the last quarter. Kathmere Capital Management LLC increased its holdings in shares of Cardinal Health by 1.2% in the 1st quarter. Kathmere Capital Management LLC now owns 4,242 shares of the company’s stock worth $896,000 after purchasing an additional 49 shares in the last quarter. Hillsdale Investment Management Inc. raised its stake in shares of Cardinal Health by 0.9% in the fourth quarter. Hillsdale Investment Management Inc. now owns 5,760 shares of the company’s stock worth $1,184,000 after purchasing an additional 50 shares during the last quarter. V Square Quantitative Management LLC raised its stake in shares of Cardinal Health by 2.6% in the first quarter. V Square Quantitative Management LLC now owns 2,002 shares of the company’s stock worth $423,000 after purchasing an additional 50 shares during the last quarter. Finally, Generali Asset Management SPA SGR lifted its holdings in shares of Cardinal Health by 11.0% during the fourth quarter. Generali Asset Management SPA SGR now owns 513 shares of the company’s stock valued at $105,000 after purchasing an additional 51 shares in the last quarter. 87.17% of the stock is owned by institutional investors.

Key Headlines Impacting Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Cardinal Health Stock Up 0.4%

Cardinal Health stock opened at $229.48 on Friday. Cardinal Health, Inc. has a 52-week low of $145.87 and a 52-week high of $258.30. The company has a market cap of $53.37 billion, a P/E ratio of 31.74, a P/E/G ratio of 1.22 and a beta of 0.49. The business has a 50-day simple moving average of $232.02 and a two-hundred day simple moving average of $217.86.

Cardinal Health (NYSE:CAH – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. The company had revenue of $63.67 billion for the quarter, compared to the consensus estimate of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.08 earnings per share. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Research analysts anticipate that Cardinal Health, Inc. will post 12.54 EPS for the current fiscal year.

Cardinal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a dividend of $0.5158 per share. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is currently 28.49%.

Insider Activity

In other news, CAO Mary C. Scherer sold 2,302 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $237.39, for a total transaction of $546,471.78. Following the completion of the sale, the chief accounting officer owned 2,811 shares of the company’s stock, valued at $667,303.29. The trade was a 45.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Deborah Weitzman sold 7,354 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total value of $1,731,499.30. Following the completion of the sale, the chief executive officer owned 77,901 shares of the company’s stock, valued at $18,341,790.45. This trade represents a 8.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 210,271 shares of company stock worth $49,626,657. Company insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth

CAH has been the topic of several recent analyst reports. Evercore reaffirmed an “outperform” rating and set a $270.00 price objective on shares of Cardinal Health in a research report on Wednesday, August 12th. Robert W. Baird upped their target price on shares of Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Weiss Ratings downgraded shares of Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a report on Wednesday. Barclays boosted their price objective on shares of Cardinal Health from $258.00 to $275.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Finally, Mizuho increased their price objective on shares of Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Cardinal Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $266.56.

View Our Latest Analysis on CAH

About Cardinal Health

(Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.